Chlordiazepoxide/Clidinium Dosage
This dosage information may not include all the information needed to use Chlordiazepoxide/Clidinium safely and effectively. See additional information for Chlordiazepoxide/Clidinium.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Additional dosage information:
Usual Adult Dose for Peptic Ulcer
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 or 2 capsules orally 3 or 4 times daily before meals and at bedtime
Usual Adult Dose for Irritable Bowel Syndrome
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 or 2 capsules orally 3 or 4 times daily before meals and at bedtime
Usual Adult Dose for Enterocolitis
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 or 2 capsules orally 3 or 4 times daily before meals and at bedtime
Usual Geriatric Dose for Peptic Ulcer
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 capsule orally twice daily
Dose may be increased gradually as needed and tolerated.
Usual Geriatric Dose for Irritable Bowel Syndrome
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 capsule orally twice daily
Dose may be increased gradually as needed and tolerated.
Usual Geriatric Dose for Enterocolitis
Chlordiazepoxide 5 mg-clidinium 2.5 mg oral capsule: 1 capsule orally twice daily
Dose may be increased gradually as needed and tolerated.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Chlordiazepoxide-clidinium is contraindicated in patients with glaucoma, prostatic hypertrophy, and benign bladder neck obstruction.
Suicide is an inherent risk in depressed patients with anxiety. Patients should be closely supervised and dispensed the smallest quantity of drug possible while receiving chlordiazepoxide.
Occasionally, blood dyscrasias (including agranulocytosis), jaundice, and hepatic dysfunction have occurred during treatment with chlordiazepoxide. During extended treatment, periodic blood counts and liver function tests are recommended.
Chlordiazepoxide is habit forming. Addiction prone individuals (such as alcoholics, and drug addicts) should be monitored closely if they receive chlordiazepoxide or other psychotropic agents because of the predisposition of such patients to habituation and dependence.
Withdrawal symptoms (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating) have occurred following abrupt discontinuation of chlordiazepoxide. The more severe withdrawal symptoms have been limited to those patients who had received excessive doses over an extended period of time. It is recommended that patients on prolonged therapies avoid abrupt discontinuation, and follow a gradual dosage tapering.
Patients with renal and/or hepatic dysfunction should be treated with chlordiazepoxide-clidinium cautiously.
Safety and efficacy of chlordiazepoxide-clidinium have not been established in pediatric patients.
Dialysis
Data not available
